Physicochemical Properties
| Molecular Formula | C73H129N29O19 |
| Molecular Weight | 1716.98827338219 |
| Exact Mass | 1716.001 |
| CAS # | 149155-45-3 |
| PubChem CID | 25092394 |
| Appearance | White to off-white solid powder |
| Density | 1.5±0.1 g/cm3 |
| Index of Refraction | 1.673 |
| LogP | -6.56 |
| Hydrogen Bond Donor Count | 28 |
| Hydrogen Bond Acceptor Count | 26 |
| Rotatable Bond Count | 59 |
| Heavy Atom Count | 121 |
| Complexity | 3510 |
| Defined Atom Stereocenter Count | 14 |
| SMILES | CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N |
| InChi Key | QKXYCULATRFTIQ-KPXMCYQPSA-N |
| InChi Code | InChI=1S/C73H129N29O19/c1-5-39(4)55(101-60(112)46(25-26-54(106)107)94-58(110)44(16-9-29-87-70(78)79)92-57(109)43(15-8-28-86-69(76)77)91-56(108)42(75)14-6-7-27-74)66(118)98-49(34-38(2)3)61(113)99-51(36-103)63(115)93-45(17-10-30-88-71(80)81)59(111)95-47(18-11-31-89-72(82)83)67(119)102-33-13-20-53(102)65(117)100-52(37-104)64(116)97-50(35-40-21-23-41(105)24-22-40)62(114)96-48(68(120)121)19-12-32-90-73(84)85/h21-24,38-39,42-53,55,103-105H,5-20,25-37,74-75H2,1-4H3,(H,91,108)(H,92,109)(H,93,115)(H,94,110)(H,95,111)(H,96,114)(H,97,116)(H,98,118)(H,99,113)(H,100,117)(H,101,112)(H,106,107)(H,120,121)(H4,76,77,86)(H4,78,79,87)(H4,80,81,88)(H4,82,83,89)(H4,84,85,90)/t39-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,55-/m0/s1 |
| Chemical Name | (4S)-5-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-4-(diaminomethylideneamino)butyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-oxopentanoic acid |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | delta-CREB is a splice variant of cAMP response element binding protein (CREB). CREBtide (KRREILSRRPSYR), a synthetic peptide based on the delta-CREB phosphorylation sequence. δ-CREB and CREBtide were explored as substrates for cAMP-dependent protein kinase (cAK). The apparent Km of CREBtide for cAK phosphorylation is 3.9 μM, which is 10 times lower than the synthetic peptide substrate Kemptide (Km=39 μM) most typically employed for cAK assays. The Vmax value of CREBtide is 12.4 mumol/(min.mg) and that of Kemptide is 9.8 mumol/(min.mg). The apparent Km of CREBtide phosphorylated by cGMP-dependent protein kinase (cGK) is 2.9 μM, and the Vmax value is 3.2 mumol/(min.mg). Compared to cAK, cGK phosphorylates delta-CREB and CREBtide significantly more slowly, implying that this peptide retains the high cAK/cGK selectivity displayed by delta-CREB [2]. |
| References |
[1]. A microPLC-based approach for determining kinase-substrate specificity. Assay Drug Dev Technol. 2007 Aug;5(4):559-66. [2]. cAMP-dependent protein kinase, but not the cGMP-dependent enzyme, rapidly phosphorylates delta-CREB, and a synthetic delta-CREB peptide. Biochem Cell Biol. 1992 Oct-Nov;70(10-11):1277-82. [3]. Cognitive impairment in Coffin-Lowry syndrome correlates with reduced RSK2 activation. Neurology. 2001 Jan 23;56(2):207-14. |
Solubility Data
| Solubility (In Vitro) | H2O : ~100 mg/mL (~58.24 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (29.12 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5824 mL | 2.9121 mL | 5.8241 mL | |
| 5 mM | 0.1165 mL | 0.5824 mL | 1.1648 mL | |
| 10 mM | 0.0582 mL | 0.2912 mL | 0.5824 mL |